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Advanced glycation end products (AGEs) are a heterogeneous group of
molecules produced, non-enzymatically, from the interaction between
reducing sugars and the free amino groups of proteins, nucleic acids, and
lipids. AGEs are formed as a normal consequence of metabolism but can also
be absorbed from the diet. They have been widely implicated in the
complications of diabetes affecting cardiovascular health, the nervous system,
eyes, and kidneys. Increased levels of AGEs are also detrimental to metabolic
health and may contribute to the metabolic abnormalities induced by the
Western diet, which is high in processed foods and represents a significant
source of AGEs. While increased AGE levels are a consequence of diabetic
hyperglycaemia, AGEs themselves activate signaling pathways, which
compromise insulin signaling and pancreatic 𝜷-cell function, thus,
contributing to the development of type 2 diabetes mellitus (T2DM).
Furthermore, AGEs may also contribute to the obesogenic effects of the
Western diet by promoting hypothalamic inflammation and disrupting the
central control of energy balance. Here, the role of dietary AGEs in metabolic
dysfunction is reviewed with a focus on the mechanisms underpinning their
detrimental role in insulin resistance, pancreatic 𝜷-cell dysfunction,
hypothalamic control of energy balance, and the pathogenesis of T2DM and
obesity.
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1. Introduction
Advanced glycation end products (AGEs)
are a complex and heterogeneous group
of protein, lipid, and DNA adducts im-
plicated in the development of numer-
ous chronic diseases including diabetes
related complications, cardiovascular, re-
nal, and neurodegenerative disease, and
have recently also been implicated in hy-
pothalamic inflammation and obesity.[1]
AGEs are produced both naturally in the
body, as part of normal metabolism, and
during the cooking and processing of
food with a significant proportion being
absorbed in the gastrointestinal tract. The
rate of AGE formation in the body is
greatly enhanced in diabetes.[2,3] Further-
more, the Western diet not only contains
large amounts of AGEs, due to high lev-
els of food processing, but is also high in
fat and sugar, particularly fructose, which
increases AGE production in the body,
in part, by increasing circulating glucose
levels via enhanced hepatic glucose pro-
duction and insulin resistance.[4] Addi-
tionally, fructose can increase AGE for-
mation independently of glucose by in-
creasing 𝛼-oxoaldehydes levels.[5]
AGEs were first described in 1912 being initially identified in
food and drink as a result of the browning effect termed theMail-
lard reaction.[6] The identification of AGEs in vivo did not occur
for the next 60 years when their formation was recognized as part
of the normal ageing process with irreversible AGEs accumula-
tion in tissues containing long-lived proteins, such as collagen in
the extracellular matrix, crystalins in the eye lens, and the base-
ment membrane in the kidney.[7–9] Excessive AGE formation is
particularly associated with cross-linking of matrix proteins such
as collagen, vitronectin, and laminin.[2,10,11] The level of AGEs in
the body increases with time due to their accumulation in pro-
teins and this process is thought to contribute to aging,[12] par-
ticularly as their formation alters the structure and function of
proteins producing the hallmark features of ageing.[13] Also, the
increased presence of AGEs in collagen across eight mammalian
species has been shown to be associated with reduced lifes-
pan, indicating that AGE levels determine lifespan and rate of
ageing.[14] More recently, AGEs have been identified as one of the
molecular mediators in the onset and progression of metabolic
dysfunction via the activation of intracellular pathways, which
promote inflammation and increased levels of reactive oxygen
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species (ROS). This reviewwill summarize themolecular process
of AGEs formation as well as their role in metabolic dysfunction.
2. AGE Formation
AGEs are synthesized endogenously as well as during food cook-
ing and processing via the Maillard reaction. This is a complex,
multistage, non-enzymatic reaction initially involving a glyca-
tion/condensation process between reducing sugars, such as glu-
cose and fructose and the free amino group of proteins, lipids,
and nucleic acids resulting in formation of a Schiff base. This re-
action is relatively fast and highly reversible. The subsequent re-
arrangement of the Schiff base leads to the formation of themore
stable Amadori products which progress to covalent adducts and
accumulate on proteins.[15] One outcome of this process, in the
body, is an Amadori product; glycated haemoglobin (HbA1c)
which is used as an accurate marker of long-term exposure to
high circulating glucose. The formation of intermediate Amadori
products is reversible (see section on AGE detoxification).
Despite its ability to react with free amino groups, glu-
cose is a poor glycating agent compared to dicarbonyls such
as methylglyoxal.[16] The Maillard reaction generates these
highly reactive dicarbonyls, also referred to as 𝛼-oxoaldehydes,
which in addition to methylglyoxal include glyoxal and 3-
deoxyglucosone.[17] These molecules can also be generated
from glucose autoxidation, lipid peroxidation, and the polyol
pathway.[18] Dicarbonyls, initiate the process of advanced glyca-
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tion leading to the synthesis of the well characterized AGEs,
N𝜖-(carboxymethyl) lysine (CML) and N𝜖-(carboxyethyl) lysine
(CEL)[18] (Figure 1).
Besides the Maillard reaction and the oxidation of glucose,
the polyol pathway represents a further mechanism leading to
the formation of AGEs. An increase in intracellular glucose lev-
els as a result of hyperglycaemia, is toxic and glucose is subse-
quently funneled toward the polyol pathway. The first step of this
pathway is the conversion of glucose to sorbitol mediated by the
enzyme aldose reductase, sorbitol is then converted to fructose
by sorbitol dehydrogenase. Over-activation of the polyol path-
way results in the depletion of NAD+, the cofactor of sorbitol
Figure 1. Formation of advanced glycation end products (AGEs). Left panel: Maillard reaction. Right panel: Alternative pathways, Hodge pathway:
fructosamine, non-oxidative Amadori product cleavage (1); Namiki pathway: cleavage of dicarbonyl compounds from aldimines (2); Wolff pathway: metal
catalyzed glucose autoxidation (3); glycolytic pathway intermediates, for example, glyceraldehyde 3 phosphate (4); polyol (sorbitol aldose reductase)
pathway (5); amino acid derived ketone body metabolism (6); lipid peroxidation (7). These pathways lead to formation of reactive dicarbonyls, which
if not detoxified form AGEs, (e.g., carboxyethyl lysine [CEL], carboxymethyl lysine [CML], glyoxal lysine dimer [GOLD], 3-deoxyglucosone lysine dimer
[DOLD], and pyrroline).
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Figure 2. Chemical structures of selected physiologically important dicarbonyl intermediates and advanced glycation end products (AGEs). Reactive
dicarbonyl AGE precursors: methylglyoxyl, glyoxyl, and 3-deoxyglucasone (1). Arginine derived AGEs: methylglyoxal-derived hydroimidazolone [MGH1],
pentosidine, and 3-3-deoxyglucosone derived imidazolone [3-DG-imadazolone]. Lysine derived AGEs: carboxyethyl lysine [CEL], carboxymethyl lysine
[CML], and pyrroline (2). AGE crosslinks: GOLD (glyoxal lysine dimer), DOLD (3-deoxyglucosone lysine dimer), pentosidine, and glucosepane (3).
dehydrogenase, which inhibits the activity of the glycolytic en-
zyme glyceraldehyde triphosphate dehydrogenase and conse-
quently promoting the accumulation of upstream metabolites,
including fructose and triose phosphates. The build-up of these
metabolites gives rise to highly reactivemolecules including fruc-
tose 3 phosphate and dicarbonyl derivatives, glyoxal, methylgly-
oxal, and 3-deoxyglucosone, which interact with intracellular and
extracellular proteins to form AGEs.[8,19] The chemical structures
of these compounds are detailed in Figure 2.
Lipid peroxidation products also form reactive carbonyls such
as malondialdehyde and methylglyoxal, derived from the oxi-
dation of polyunsaturated fatty acids. Additionally, reactive car-
bonyls are formed from ketones generated by breakdown of
amino acids, including the formation ofmethylglyoxal from thre-
onine catabolism. Thus, reactive carbonyl groups are constantly
being produced via normal metabolism and when production
overrides detoxification, AGEs accumulate. AGE formation may
take several days or weeks to complete in the body[20,21] with fi-
nal AGE concentration depending on the half-life of the glycated
proteins.
The amino residues arginine, lysine and, to a lesser extent, cys-
teine and the nucleotides guanosine and deoxyguanosine are par-
ticularly vulnerable to dicarbonyl modification[22] forming AGEs
and DNA-AGEs such as N2(1-carboxyethyl)-2′-deoxyguanosine
(CEdG). Some of the most commonly formed AGEs include the
hydroimidazolones, the most prevalent of these in human tis-
sues is formed from the interaction of methylglyoxal with argi-
nine residues.[23] Other prevalent AGEs are CML and CEL. How-
ever, less common AGEs such as, pentosidine (very elevated in
uraemia and a good marker of “carbonyl stress”), pyrraline, and
glucosepane are found at much lower levels, but also play a role
in human disease risk[24,25] (Figures 1 and 2).
3. Source and Absorption of Dietary AGEs
Dietary AGEs are formed during the cooking, processing, and
storage of foods as a result of the non-enzymatic browning,
Maillard reaction, between a carbonyl group of a reducing sugar
and a primary amine group as shown in Figure 1 and described
in detail earlier. Factors affecting the AGE content of food
depends on the content of protein, fat, and sugar and the types
of processing and cooking methods employed, predominantly
on the temperature and duration of preparation.[26,27] Prolonged
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high temperatures such as those used in the processing of
some dairy products and cooking techniques like roasting and
frying increase the production of dietary AGEs.[26,27] When CML,
CEL, and MG-H1 are measured by ultra-performance liquid
chromatography tandem mass spectrometry, food items such as
peanuts, biscuits, cereals, toast, and heat-processed meats have
the highest levels, ranging from 2–5 mg for CML, from 2–7 mg
for CEL, and from 15–60 mg for MG-H1 per 100 g, in contrast
coffee, fruits, vegetables, butter, olive oil, and red wine contain
negligible amounts of these AGEs.[27]
Dietary AGEs are absorbed by the gastrointestinal tract to ex-
ert their effects on health with dietary and circulating free-AGEs
concentrations highly correlated,[28–30] making free-AGEs a good
marker for dietary AGE intakewhile plasma protein-boundAGEs
better represent endogenously produced AGEs.[31] The hetero-
geneity of dietary AGEs makes it challenging to predict their rate
of absorption or pinpoint potential transporters. Nonetheless, the
rate and the mechanisms of absorption of CLM, CEL, pentosi-
dine, and pyrraline have been reported with around 10–30% be-
ing absorbed depending on their chemical characteristics.[28–30]
AGEs can reach the gastrointestinal tract as free AGEs, which in-
clude amino acids and small peptides with a molecular weight
lower than 5 kDa or bound to proteins as high-molecular weight
complexes.[30,32] Free CML is absorbed by simple diffusion,[33]
with dipeptides requiring the peptide transporter 1,[34] which also
transports pyrraline dipeptides.[35] Thus, the absorption of AGEs
as single amino acids or dipeptides occurs more efficiently than
protein-bound AGEs, evidenced by higher levels of CML in the
faeces when protein-bound CML is ingested.[36] The same is true
for the AGE pentosidine the absorption of which is greater when
derived from brewed coffee (free-form) compared to bakery prod-
ucts where pentosidine occurs as a protein-bound AGE.[37]
AGE modification inhibits proteolytic digestion[32,38] thus,
low molecular weight AGEs are absorbed more efficiently than
protein-bound AGEs.[39] Nonetheless, albeit at a lower rate,
protein-bound AGE absorption still does take place. This was
demonstrated in rodents where organ accumulation of dietary
13C-labeled CML occurs following feeding 13C-labeled-CML-
BSA.[40] The presence of 13C-labeled CML in the faeces indicates
that AGEs have the potential to interact with the gut microbiota
which has been extensively reviewed elsewhere.[29]
4. Receptors for AGEs
4.1. RAGE
AGEs are ligands for several receptors, themain one being the re-
ceptor for advanced glycation end products (RAGE). Full-length,
membrane bound RAGE (mRAGE) is present on numerous cell
types throughout the body while soluble RAGE (esRAGE), pro-
duced via alternative splicing and lacking a transmembrane do-
main, is found in the circulation. A separate soluble receptor is
ectodomain-shed RAGE (ecRAGE), which is derived via the ac-
tion of metalloproteases on mRAGE.[41] All three isoforms of the
receptor are equally effective in binding ligands, however the two
secreted forms of RAGE lack the capacity to elicit the activation of
the intracellular signal transduction pathways activated by AGEs.
Furthermore, the soluble forms of the RAGE competitively bind
AGEs preventing their interaction with mRAGE and the ac-
tivation of downstream pathways, including pro-inflammatory
responses.[42,43]
RAGE belongs to the immunoglobulin superfamily of pattern
recognition receptors and is not exclusively stimulated by AGEs
but can also be activated by other intracellular and extracellular
ligands. mRAGE is a surface receptor and expressed on a variety
of cells, including peripheral immune cells, but also in the mi-
croglia, endothelial cells, smooth muscle cells, and neurons.[1,44]
As AGEs comprise such a diverse and heterogeneous group
of compounds, information relating to specific interactions be-
tween different AGEs and RAGE are limited. mRAGE consists
of extracellular hydrophobic transmembrane and cytoplasmic do-
mains with the extracellular structure of mRAGE further sub-
divided into three immunoglobulin-like domains: a variable (V)
domain and two constant C1 and C2 domains. mRAGE inter-
acts with AGEs, such as CML, CEL, which bind to the V domain
of mRAGE to trigger an immunoinflammatory response. CML
and CEL can only bind to mRAGE if they are incorporated into
larger peptide structures.[45,46] Chemically synthesized peptides
containing hydroimidazolones bind specifically to the V domain
of mRAGE resulting in signal transduction. In contrast to CML
or CEL, the hydroimidazolone MG-H1 does not require attach-
ment to a peptide carrier to exert its effect[47] and as the MG-H1
content of foods is much higher than either CML or CEL, free
MG-H1 absorbed from the diet is likely to be a significant activa-
tor of mRAGE.[27,48]
Upon binding to their cognate receptor, AGEs trigger the acti-
vation of different downstream effectors, including extracellular-
signal-regulated kinase 1/2 and p38 mitogen-activated protein
kinase, rho-GTPases, Janus kinase, c-Jun N-terminal kinase
(JNK), and the transcription factor nuclear-factor-kappa B (NF-
𝜅B).[49–53] Besides activating inflammatory pathways, the activa-
tion of RAGE is also implicated in promoting oxidative stress
by activating NAPDH oxidase which enhances ROS production
with ROS promoting AGE formation.[18,54] Moreover, ROS poten-
tiate the inflammatory response by activatingNF-𝜅B,which, once
activated, migrates to the nucleus and induces not only the ex-
pression of inflammatorymediators, but also upregulates RAGE,
thus establishing a positive feedback loop.[55,56] mRAGE has also
been shown to transport 𝛽-amyloid into neurons[57] and to fa-
cilitate the gut uptake of oxytocin from milk and the transport
of circulating oxytocin into the brain, indicating that it mediates
physiological as well as pathological effects[58,59] (Figure 3).
4.2. Other Receptors
AGEs can also bind to other cell surface receptors in addition
to RAGE. These receptors mediate endocytosis and the degra-
dation of AGEs to maintain AGE homeostasis and include the
cluster of differentiation 36, macrophage scavenger receptors
I and II, and the advanced glycation end products receptors
(AGER1, AGER2, and AGER3).[60] AGER1 is present in almost
all cells and tissues, is upregulated by AGEs and increases their
uptake and removal.[18] AGER1 can counteract AGE-induced
oxidative stress[61,62] as well as inhibit the activation of NF-𝜅B by
promoting a sirtuin1-dependent deacetylation and suppression
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Figure 3. Receptor for advanced glycation end products (RAGE): RAGE signals via the transcription factor nuclear-factor-kappa B (NF-𝜅B) increasing
gene expression of inflammatory mediators and the production of ROS. Full-length, membrane bound RAGE (mRAGE), soluble RAGE (esRAGE) is found
in the circulation. Ectodomain-shed RAGE (ecRAGE) is derived via the action of metalloproteases (MMP) on mRAGE. All three isoforms of the receptor
are equally effective in binding ligands however, the two secreted forms of RAGE lack the capacity to elicit any signaling mechanisms.
of NF-𝜅B.[63,64] Nonetheless, this protective mechanism begins
to fail as the concentration of AGEs increases, with high lev-
els of AGEs leading to a downregulation of both AGER1 and
sirtuin1.[64]
The close structural and functional RAGE homologue,
CD116/activated leukocyte cell adhesion molecule (ALCAM),
elicits the inflammatory effects of AGEs when RAGE is absent[65]
and ALCAM expression is upregulated by CML challenge when
RAGE activation is blocked.[66] In mice, where AGEs were iden-
tified as being the mechanism by which a high-fat diet causes
hypothalamic inflammation, knockdown of both RAGE and AL-
CAM was required to block the proinflammatory effects of
CML.[1]
5. Detoxification of AGEs
The toxicity of the dicarbonyl precursors of AGEs is underlined
by the numerous mechanisms that the body employs to remove
them. It has been estimated that around 99% of all methyl-
glyoxal is broken down via the glyoxalase pathway[67] detailed
below.
5.1. Glyoxalases (GLO1 and 2)
The glyoxolase system is well characterized and comprises two
enzymes; glyoxalases 1 and 2 (GLO1 and 2), which require
the thiohemiacetal produced by the non-enzymatic reaction
between glutathione and a 2-oxoaldehyde, particularly methyl-
glyoxal, as a substrate.[68] This system acts to convert the dicar-
bonyls; glyoxal and methylglyoxal to lactic and glycolic acid, re-
spectively. Activity of the glyoxolase is upregulated in diabetes
to prevent the build-up of reactive dicarbonyls thereby suppress-
ing AGE formation.[69] However, the scavenging capacity of this
system can be overridden by an increase in dicarbonyl forma-
tion, leading to dicarbonyl stress which results in enhanced AGE
production.[70,71]
Underlining the deleterious effect of dicarbonyl stress at
the cellular levels, over expression of GLO1 in cultured cells
and model organisms prevents hyperglycemia induced oxida-
tive stress and AGE accumulation while a reduction in GLO1
expression using siRNA is associated with elevated levels of
methylglyoxal-derived hydroimidazolone 1 protein adducts
and increases in pathological changes associated with diabetic
nephropathy.[72] Furthermore, silencing GLO1 in endothelial
cells has been reported to upregulate genes linked with coronary
heart disease[73] as well as resulting in glucose intolerance, oxida-
tive stress, and decreased lifespan in Caenorhabditis elegans.[74,75]
Thus, the glyoxalase detoxifying system is pivotal in main-
taining dicarbonyl homeostasis and preventing the formation
of AGEs.
5.2. DJ-1 Deglycase (GLO3)
The role of DJ-1/PARK7 is more contentious. The protein has
been shown to have numerous roles and is referred to as a
multifunctional stress response protein[76] acting as a covalent
chaperone for the thiol proteome[77] a chaperone for synuclein,[78]
a protease and as a cofactor-independent glyoxalase.[79] How-
ever, it has been argued these functions are much weaker
than major proteins, which normally fulfill these roles.[76,79,80]
More recently DJ-1 has been shown to be important in the
carbonyl stress response acting as a protein deglycase repairing
methylglyoxal- and glyoxal-glycated proteins and amino acids,
releasing deglycated products plus lactate or glycolate.[81] DJ-1
is also reported to be important in reversing DNA glycation and
has subsequently been renamed as the DJ-1 family of Maillard
deglycases.[82,83]
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5.3. Other Enzymes
Other enzymes have been identified for their capability to break
down dicarbonyls and rid the organism of damaged proteins,
with minor metabolism by aldo–keto reductases and aldehyde
dehydrogenases.[84] While knockdown of any of these enzymes
can cause upregulation of the dicarbonyls in the short-term, their
absence does not appear to have any pathological consequences
and their activity seems to be important only when AGE levels
are low.[85–88]
The enzymes and detoxifying systems described so far are re-
sponsible for neutralizing AGE precursors, thus preventing or
retarding AGE formation. However, AGEs, once formed can also
be degraded. Dietary AGEs which are the result of digestion
and absorption are likely to be “free” either as glycated peptides
or amino acids while endogenously formed AGES can also be
adducts of cellular proteins and may be broken down via protea-
somal degradation as indicated by an increased release of prote-
olytic products of glycated proteins in response to increased levels
of glycated proteins in type 1 diabetes.[88] AGEs can also be taken
up by the cells, via receptor-mediated endocytosis, and degraded
by the endosomal–lysosomal system and particularly by the en-
zymes cathepsin L and D.[89] Initially, the AGE–RAGE complex is
internalized via clathrin-dependent mechanism, clathrin-coated
vesicles are then transported to endosome where, the drop in pH
leads to the release of the AGE–RAGE binding with the receptor
being recycled back to the cell membrane. Endosomes contain-
ing AGEs fuse with lysosomes where AGEs are degraded by the
lysosomal proteases cathepsin L and D.[52]
A further mechanism implicated in preventing AGE-induced
toxicity, independent of AGE degradation and dicarbonyl detoxifi-
cation, is the upregulation of AGER1 as stated earlier (see Section
4).
6. AGEs and the Western Diet
The Western diet is associated with the increased incidence of
obesity and obesity-related diseases. The relationship between
diet and metabolic dysfunction is poorly understood, but it ap-
pears that the combination of refined carbohydrates and long-
chain saturated fat is key. The quantity of highly processed
food consumed globally has greatly increased spanning most
of the food categories including snacks, reconstituted meat,
and soft drinks.[90] There is an association between elevated in-
take of highly processed food and cardiovascular disease[91] and
mortality,[92] both linked to excessive calorie intake and weight
gain[93] but also involving unidentified mechanisms. Highly pro-
cessed foods are relatively inexpensive, have long shelf lives, and
are microbiologically safe and highly convenient.[94] However,
food processing involves the exposure of food to high temper-
atures for prolonged periods of time increasing the formation of
AGEs.[95]
There is some debate as to the relative importance of dietary
AGEs with limited digestion and absorption by the gastrointesti-
nal tract, particularly of high molecular weight AGEs while low
molecular dietary AGEs appear to be efficiently disposed of by
the kidneys. Nonetheless the restriction of dietary AGEs has been
associated with reductions in inflammation and an increase in
vascular function in humans,[96,97] while high loads of dietary
AGEs have been associated with premature cognitive decline in
humans[98] and in animal models fed a high MG diet equivalent
to 19 𝜇mol per day.[99] Also feeding NF-𝜅B-luciferase transgenic
mice with AGE modified albumin leads to a systemic activation
of inflammation.[100] Taken together, these studies strongly impli-
cate dietary AGEs inmetabolic dysfunction. However, in contrast
two feeding studies showed no effect of dietary AGEs on inflam-
matory and cardiovascular profiles in humans.[101,102]
A suggested strategy to limit dietary AGE ingestion is the use
of DJ-1 deglycases, especially those from thermophilic organ-
isms, to prevent the formation of dietary AGEs during food pro-
cessing, sterilization, and storage. This class of enzymes would
also prevent acrylamide formation in food, likely by degrad-
ing the asparagine/glyoxal Maillard adducts responsible for its
formation.[103]
Components of the Western diet itself may increase endoge-
nous formation of AGEs. Increased consumption of sucrose, a
disaccharide composed of fructose and glucose, is associatedwith
the development of obesity and related diseases. Glucose is the
most abundant sugar in the circulation, giving rise to AGEs with
its high concentration in diabetes overcoming its relative inac-
tivity. However, the much more reactive dicarbonyls (2–3 times
more reactive than glucose) which are only present in much
lower amounts are considered the major drivers of AGE forma-
tion leading to the concept of dicarbonyl stress when formation
exceeds the bodies capacity to detoxify them (see Section5).
Themore recent widespread use of fructose as part of theWest-
ern diet[104] is highly associated with metabolic syndrome.[105,106]
When relatively low levels of fructose are present in the diet, it
is metabolized by the small intestine to form glucose and lactate,
but higher dietary levels travel to the liver where it ismetabolized,
first to lactate and glucose, and the excess glucose was converted
to lipid. When physical activity is high fructose derived glucose
and lactate are efficiently metabolized in muscle.[107] While cir-
culating levels of fructose are much lower than those of glucose,
their intracellular levels are similar. However, in diabetes, where
the polyol pathway is active, concentrations of fructose are ele-
vated and are thought to be responsible formany of the complica-
tions of raised blood glucose.[108] It should be noted that glucose
has the slowest rate in the glycation reaction of any sugar in cells
while the rate for fructose-dependent intracellular formation of
AGEs is 7.5-fold faster than that of glucose.[109]
It is important to note that there are intrinsic problems in
comparing AGE concentrations across studies particularly those
that measure the AGEs content of foods.[110] These discrepancies
are due to the use of different measurement techniques as
well as the influence of food matrixes on AGE values obtained.
Many of the initial studies on AGE content have used immuno-
based techniques, including ELISA which do not give absolute
values[95] with some assays for measuring AGEs employing anti-
bodies raised against glycated proteins such as AGE-RNase[111] or
glyceraldehyde-derived AGE-BSA[112] rather than to specific AGE
structures, for example, CML. However, the mass spectrometry
techniques used now give absolute concentrations for AGEs
such as CML meaning that values can be compared between
studies carried out using this methodology.[27,48,110] The same is
true for measuring AGEs concentrations in plasma, although to
a lesser extent. Thus, care should be taken when comparing AGE
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concentrations from different studies. Comparative values for
AGEs using these different methodologies have been extensively
reviewed elsewhere.[113]
7. AGEs in Metabolic Health: From Type 2
Diabetes to Obesity
7.1. Insulin Resistance and Type 2 Diabetes Mellitus
There is growing evidence of the impact of AGEs on metabolic
health. Indeed, apart from playing a pivotal role in diabetic
complications, including cardiovascular, kidney and neurode-
generative diseases such as Alzheimer’s and Parkinson’s dis-
ease, AGEs have also been implicated in the pathogenesis of in-
sulin resistance and type 2 diabetes mellitus (T2DM) as well as
obesity.[1,18,114–118]
T2DM is a metabolic disorder, which accounts for 90%
of the over 400 million individuals affected by diabetes
worldwide (https://www.who.int/news-room/fact-sheets/detail/
diabetes). It is characterized by chronically elevated circulating
glucose levels which arise from a state of insulin resistance in
concert with pancreatic 𝛽-cell dysfunction. Insulin resistance, the
hallmark of T2DM, is described as a blunted response of target
tissue to insulin. This results in impaired glucose uptake and
glycogen synthesis in the skeletal muscle, increased hepatic glu-
cose production and a decrease in glycogen synthesis in the liver,
inhibition of glucose uptake and increased lipolysis in the adi-
pose tissue and impaired control of peripheral glucose homeosta-
sis by the brain. Although, insulin resistance is initially counter-
acted by a compensatory insulin hypersecretion, when this com-
pensatory response becomes impaired, due to pancreatic 𝛽-cells
dysfunction, overt T2DMmanifests. AGEs can contribute to both
pathogenetic features of T2DM by promoting inflammation and
oxidative stress in humans.[18]
The low-grade chronic inflammation associated with obesity
may be one of the mechanistic links between AGEs and insulin
resistance.[118,119] Inflammation promotes insulin resistance by
activating intracellular pathways, which in turn, interfere with
the insulin signal transduction pathway. Particularly, the acti-
vation of JNK has been shown to impair insulin signaling by
promoting threonine/serine phosphorylation of insulin recep-
tor substrate (IRS),[120] similarly the activation of the I𝜅B kinase
(IKK)/NF-𝜅B signaling pathway has also been shown to inhibit
insulin signaling.[121] Importantly, AGEs activate both JNK as
well as the IKK/NF-𝜅B signaling pathway supporting the rela-
tionship between AGEs and insulin resistance.
In addition to inflammation, the AGE-RAGE axis also triggers
oxidative stress, which is associated with the development of in-
sulin resistance.[122,123] The link between AGEs and insulin resis-
tance has been corroborated in studies using animal models. In
these studies mice fed a high-AGE diet containing synthetic MG-
BSA at 1 mg per g of diet showed a decrease in insulin receptor
and IRS phosphorylation, and defective downstream activation
of AKT in skeletal muscle, adipose tissue, and liver.[64]
In skeletal muscle, a tissue pivotal for the control of glucose
homeostasis, AGEs downregulate GLUT4 and promote the acti-
vation of inflammatory pathways as well as endoplasmic reticu-
lum stress as indicated by the upregulation of nuclear factor NF-
kappa-B p50 subunit and 78 kDa glucose-regulated protein.[124]
Additionally, in both animal models and human studies expo-
sure to high levels of dietary AGEs during fetal development
has been shown to trigger metabolic reprogramming which
leads to the development of T2DM independently of any genetic
predisposition.[125,126]
The detrimental effect of dietary AGEs on insulin sig-
naling in humans has also been demonstrated,[125] with an
AGE-restricted diet improving insulin sensitivity in T2DM
with a normalization of the expression of AGER1 and sir-
tuin1 as well as a decrease in NF-𝜅B acetylation circulat-
ing TNF𝛼, serum AGEs, and leptin.[63] AGE also directly
impact onmitochondrial oxidativemetabolism via the downregu-
lation of sirtuin1 which, in turn, deacetylates and activates perox-
isome proliferator-activated receptor 𝛾 co-activator 1𝛼 (PGC 1𝛼),
the master regulator of mitochondrial oxidative metabolism.[127]
PGC 1𝛼 regulates mitochondrial energy metabolism and bio-
genesis, thus playing a pivotal role in modulating mitochondria
bioenergetics, which has been reported to be impaired in indi-
viduals affected by T2DM.[128,129] This results in defective oxida-
tive metabolism and impaired ability to completely oxidize fatty
acid thus favoring the intramyocellular accumulation of lipotoxic
lipid species and metabolites derived from the incomplete oxi-
dation of fatty acids which hamper insulin signaling.[130–132] Im-
portantly, PGC 1𝛼 appears to be instrumental in this process as
genes under its control are downregulated in individuals suf-
fering from T2DM and its upregulation has also been shown
to have insulin sensitizing effects in vitro as well as in animal
models.[129,132,133,134]
Thus, given the role of AGEs in disrupting SIRT1 expres-
sion and the importance of this NAD-dependent deacetylase
in regulating PGC 1𝛼 function, defective mitochondria bioen-
ergetics may represent another plausible mechanism linking
AGE overload and insulin resistance. The impact of AGEs on
insulin resistance in humans has also been confirmed using
hyperinsulinemic-euglycemic clamps, the gold standard for the
assessment of insulin sensitivity[48] with a low AGE diet inducing
an improvement in insulin sensitivity compared to a diet high in
AGEs, which decreases insulin sensitivity.[48] Additionally high
circulating AGE levels are associated with insulin resistance[111]
and correlate with HOMA-IR in nondiabetic subjects.[112] Taken
together, the evidence so far supports the role of AGEs as drivers
of the detrimental effects of a Western diet on metabolic health.
AGEs also contribute to pancreatic 𝛽-cell dysfunction, an-
other key component in the pathogenesis of T2DM. AGEs
exert cytotoxic effect on 𝛽-cells and induce apoptosis, which
may be dependent on ROS production. Studies using primary
𝛽-cells and cell lines demonstrate that inhibition of RAGE or
antioxidant treatment prevents AGE-induced cell toxicity.[135]
Cell culture studies also showed that the molecular mechanism
responsible for AGE-induced oxidative stress relies on increased
mitochondrial ROS production as well as the activation of
JNK which, in turn, activates NADPH oxidase further fueling
oxidative stress.[136] Additionally, in a mouse model in which dif-
ferent doses of AGE-BSA were administered by intraperitoneal
injection, AGEs not only exerted a cytotoxic effect on pancreatic
𝛽-cells, but also impaired glucose-induced insulin secretion.
ATP-mediated K+ channels closure and 𝛽-cell depolarization is
pivotal in mediating insulin secretion from pancreatic 𝛽-cells.
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AGEs, by inhibiting mitochondrial cytochrome oxidase,[137] com-
promise 𝛽-cell ATP synthesis capacity causing an impairment
in ATP-induced shutdown of K+ channels, 𝛽-cell depolarization
and consequently the influx of Ca2+ thereby preventing the
exocytosis of insulin-containing granules.[138]
Another mechanism which, albeit in part, underlies the
ability of AGEs to inhibit insulin secretion is the activation of
P38/mitogen-activated protein kinase (MAPK) and the down-
stream disturbance of microtubule dynamics marked by an
increase in microtubule depolymerization in pancreatic 𝛽-cells
in culture.[139] Finally, AGEs have been reported to interfere
with 𝛽-cell insulin secretion by directly targeting insulin tran-
scription with a mechanism, which appears to be depended on
FOXO-1-induced inhibition of pancreatic-duodenal homeobox
factor-1.[140]
7.2. AGEs in the Pathogenesis of Obesity
AGEs, beside their well-documented role in promoting insulin
resistance and T2DM, also play a putative role in the pathogen-
esis of obesity indicated by their ability to induce an increase in
body weight in adults in a 5 year follow-up study.[117] Importantly,
the ability of AGEs to increase body weight was retained after ad-
justing for total energy intake and other cofounders, suggesting
AGEs directly affect energy balance. This is also supported by the
profound impact that diets rich in highly processed food have on
body weight by increasing energy intake.[93]
Energy balance is controlled by an intricate, finely-tuned neu-
roendocrine system.[141,142] The hypothalamus receives and in-
tegrates central and peripheral information related to the nu-
tritional status of the individual and responds to these neu-
ral, nutritional, and hormonal cues by triggering orexigenic and
anorexigenic responses in order to preserve energy homeostasis
and maintain body weight within a tight range.[142] Insulin and
leptin are the main anorexigenic hormones and inform the hy-
pothalamus, particularly the arcuate nucleus of the hypothala-
mus (ARC), the master regulator of energy balance, about long-
and short-term energy status.[143,144] The ARC encompasses two
main neuronal population, the anorexigenic neurons expressing
proopiomelanocortin (POMC) and cocaine and amphetamine-
regulated transcript (CART), and the orexigenic neurons which
express neuropeptide Y (NPY) and agouti-related peptide (AgRP).
Leptin and insulin exert their anorexigenic effects by activating
POMC/CART while inhibiting NPY/AgRP expressing neurons
thus resulting in a decrease in food intake and an increase in
energy expenditure.
In light of the central role of insulin in regulating energy
balance, insulin resistance may be a mechanism underpinning
the ability of AGEs to disrupt hypothalamic control of energy
balance.[63,131,133] AGEs can also activate pro-inflammatory path-
ways; JNK and IKK/NF-𝜅B both of which have been impli-
cated in mediating high-fat diet induced hypothalamic insulin
and leptin resistance leading to hypothalamic dysfunction.[145–149]
Thus, inflammation represents a further potential mechanism,
by which AGEs disrupt energy balance leading to body weight
gain. In support of this, a diet high in both lipids and carbohy-
drates is required to induce a significant increase in hypothala-
mic inflammation in rodents associated with an increase in body
weight.[1,150] The high-fat and high-carbohydrate diet also caused
an increase in CML immunoreactivity in both POMC and NPY
neurons. It is postulated that AGEs released by hypothalamic
neurons promote inflammatory responses by targetingmicroglia
and increasing hypothalamic microgliosis,[1] a central process in
high-fat diet-induced hypothalamic dysfunction.[148] The role of
AGEs in promoting hypothalamic inflammation was confirmed
in animals lacking RAGE and ALCAM which have an improved
metabolic phenotype and decreased microglial reactivity on a
high-fat diet.[1]
8. Conclusions
AGEs are adducts formed during cooking and food processing
or produced endogenously as a consequence of metabolism. The
Western diet contains elevated levels of highly processed foods
and as such represents a source of AGEs, which contributes
to promoting obesity, insulin resistance, and deterioration in
metabolic health. The deleterious effects of AGEs are under-
pinned by their ability to trigger mechanisms well known to elicit
metabolic dysfunction, including the activation of inflammatory
pathways, oxidative stress, and impaired mitochondrial oxidative
metabolism. Although, most of the evidence related to the role of
AGEs in metabolic health highlights their role in promoting in-
sulin resistance and 𝛽-cell dysfunction, emerging evidence sup-
ports the possibility that AGEs may directly impact upon the hy-
pothalamic control of energy balance leading to body weight gain
and metabolic dysfunction. Thus, strategies aimed at preventing
or reducing AGE production during food processing and cooking
or preventing the endogenous accumulation of AGE precursors,
for example, the dicarbonyls, may represent a further strategy to
implement in order to mitigate the impact of the Western diet on
metabolic health.
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